Junhao Wen,Zhijian Yang,Ilya M. Nasrallah,Yuhan Cui,Guray Erus,Dhivya Srinivasan,Ahmed Abdulkadir,Elizabeth Mamourian,Ioanna Skampardoni,Gyujoon Hwang,Ashish Singh,Mark Bergman,Jingxuan Bao,Erdem Varol,Zhen Zhou,Aleix Boquet-Pujadas,Jiong Chen,Arthur W. Toga,Andrew J. Saykin,Timothy J. Hohman,Paul M. Thompson,Sylvia Villeneuve,Randy Gollub,Aristeidis Sotiras,Katharina Wittfeld,Hans J. Grabe,Duygu Tosun,Murat Bilgel,Yang An,Daniel S. Marcus,Pamela LaMontagne,Tammie L. Benzinger,Susan R. Heckbert,Thomas R. Austin,Lenore J. Launer,Mark Espeland,Colin L Masters,Paul Maruff,Jurgen Fripp,Sterling C. Johnson,John C. Morris,Marilyn S. Albert,R. Nick Bryan,Susan M. Resnick,Luigi Ferrucci,Yong Fan,Mohamad Habes,David Wolk,Li Shen,Haochang Shou,Christos Davatzikos

Abstract:Alzheimer’s disease (AD) is associated with heterogeneous atrophy patterns. We employed a semi-supervised clustering technique known as Surreal-GAN, through which we identified two dominant dimensions of brain atrophy in symptomatic mild cognitive impairment (MCI) and AD patients: the “diffuse-AD” (R1) dimension shows widespread brain atrophy, and the “MTL-AD” (R2) dimension displays focal medial temporal lobe (MTL) atrophy. Critically, only R2 was associated with widely known sporadic AD genetic risk factors (e.g., APOE ε4 ) in MCI and AD patients at baseline. We then independently detected the presence of the two dimensions in the early stages by deploying the trained model in the general population and two cognitively unimpaired cohorts of asymptomatic participants. In the general population, genome-wide association studies found 77 genes unrelated to APOE differentially associated with R1 and R2. Functional analyses revealed that these genes were overrepresented in differentially expressed gene sets in organs beyond the brain (R1 and R2), including the heart (R1) and the pituitary gland, muscle, and kidney (R2). These genes were enriched in biological pathways implicated in dendritic cells (R2), macrophage functions (R1), and cancer (R1 and R2). Several of them were “druggable genes” for cancer (R1), inflammation (R1), cardiovascular diseases (R1), and diseases of the nervous system (R2). The longitudinal progression showed that APOE ε4 , amyloid, and tau were associated with R2 at early asymptomatic stages, but this longitudinal association occurs only at late symptomatic stages in R1. Our findings deepen our understanding of the multifaceted pathogenesis of AD beyond the brain. In early asymptomatic stages, the two dimensions are associated with diverse pathological mechanisms, including cardiovascular diseases, inflammation, and hormonal dysfunction – driven by genes different from APOE – which may collectively contribute to the early pathogenesis of AD.### Competing Interest StatementDAW served as Site PI for studies by Biogen, Merck, and Eli Lilly Avid. He has received consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by Functional Neuromodulation. AJS receives support from multiple NIH grants, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177. He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, in kind contribution of PET tracer precursor, Bayer Oncology Scientific Advisory Board, Eisai Scientific Advisory Board, Siemens Medical Solutions USA, Inc. Dementia Advisory Board, Springer-Nature Publishing Editorial Office Support as Editor in Chief, Brain Imaging, and Behavior. ME receives support from multiple NIH grants, the Alzheimers Association, and the Alzheimer Therapeutic Research Institute. HJG has received travel grants and speaker honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. HJG had personal contracts approved by the university administration for speaker honoraria and one IIT with Fresenius Medical Care. AA was supported by grants 191026 and 206795 from the Swiss National Science Foundation

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

Predicting early Alzheimer's with blood biomarkers and clinical features

Computational Integration of Nanoscale Physical Biomarkers and Cognitive Assessments for Alzheimer’s Disease Diagnosis and Prognosis

A deep generative multimodal imaging genomics framework for Alzheimer's disease prediction

Classifying Alzheimer's disease with brain imaging and genetic data using a neural network framework

Exploring the power of MRI and clinical measures in predicting Alzheimers disease neuropathology

Multi-scale Graph-based Grading for Alzheimer's Disease Prediction

Disentangling Alzheimer's disease neurodegeneration from typical brain aging using machine learning

Predictive classification of Alzheimer’s disease using brain imaging and genetic data

Predictive Modeling Of Alzheimer's Disease Prognosis Using Anatomical & Diffusion MRI

A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation

CHARACTERIZING STRUCTURAL BRAIN ALTERATIONS IN ALZHEIMER’S DISEASE PATIENTS WITH MACHINE LEARNING

Machine learning on longitudinal multi-modal data enabling the understanding and prognosis of Alzheimer’s disease progression

Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Predicting changes in brain metabolism and progression from mild cognitive impairment to dementia using multitask Deep Learning models and explainable AI

Current Understanding of Alzheimer's Disease on Biomarkers, Magnetic Resonance Imaging Modalities, and Diagnosis, Prevention, and Treatment Approach

c-Diadem: a constrained dual-input deep learning model to identify novel biomarkers in Alzheimer's disease

An interpretable generative multimodal neuroimaging-genomics framework for decoding Alzheimer's disease

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage

Development and validation of a deep learning framework for Alzheimer’s disease classification